Rallybio Corporation · NASDAQ:RLYB
Rallybio — Corporate Update (December 2023)
6 slides from Rallybio's corporate update, Dec 20, 2023
Slide 1: RLYB116
Exhibit 99.2 ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ RLYB116
Slide 2: RLYB116 adverse events by preferred term (single dose cohorts)
• • • AE preferred term RLYB116 Placebo N=10 n (%) All N=40 n (%) 2 mg N=6 n (%) 10 mg N=6 n (%) 30 mg N=6 n (%) 100 mg N=6 n (%) 300 mg N=6 n (%) Gastrointestinal disorders Abdominal pain/discomfort 2 (33.3) 2 (33.3) 4 (10.0) Diarrhea 1 (16.7) 1 (16.7) 3 (50.0) 1 (10.0) 6 (15.0) Nausea/Vomiting 2 (
Slide 3: RLYB116
RLYB116 • • • • ▪ ▪ ▪ ▪ Source: Rallybio IPC2001 data
Slide 4: Source: Rallybio IPC2001 data Source: Rallybio IPC2001 data Source: Rallybio IPC2001 data Source: Rallybio
Source: Rallybio IPC2001 data Source: Rallybio IPC2001 data Source: Rallybio IPC2001 data Source: Rallybio IPC2001 data
Slide 5: AE System Organ Class and Preferred Terms
AE System Organ Class and Preferred Terms RLYB116 Placebo N=9 n (%) All N=49 n (%)100 mg QW N=10 n (%) 100 mg induction N=10 n (%) 150/125 mg QW N=10 n (%) 75/100 mg BIW N=10 n (%) Gastrointestinal disorders Abdominal pain/discomfort 2 (20.0) 2 (20.0) 2 (20.0) 6 (12.2) Diarrhea 1 (10.0) 2 (20.0) 3 (
Slide 6: RLYB116: Summary and Plan Forward
(BD RLYB116: Summary and Plan Forward * Reduction in free C5 with 100 mg weekly dose in MAD study has the potential to be effective for patients with gMG * Market research supports that a once weekly, small volume, and rapid self- administered therapeutic has the potential to address unmet need for
Rallybio — Corporate Update (December 2023) on 6ix